drugset / Trial / NCT04013672
Study of Pembrolizumab Plus SurVaxM for Glioblastoma at First Recurrence
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The main purpose of this study is to assess the clinical activity of Pembrolizumab and SurVaxM in participants with recurrent glioblastoma.
Timeline
- Start
- 2020-03-19
- Primary completion
- 2021-08-16
- Completion
- 2022-02-16
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pembrolizumab | Monoclonal antibody | 200 mg | Intravenous |
| Subject | SVN53-67/M57-KLH Peptide Vaccine | Vaccine | 500 ug | — |
| Background | incomplete Freund's adjuvant | Other / unclassified | 1 ml | — |
| Background | sargramostim | Protein / enzyme biologic | 100 ug | — |